Codi QR

MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy

<p>Abstract</p> <p>Background</p> <p>The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O<sup>6</sup>-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic si...

Descripció completa

Guardat en:
Autors principals: Melguizo Consolación, Prados Jose, González Beatriz, Ortiz Raul, Concha Angel, Alvarez Pablo, Madeddu Roberto, Perazzoli Gloria, Oliver Jaime, López Rodrigo, Rodríguez-Serrano Fernando, Aránega Antonia
Format: Artigo
Idioma:Inglês
Publicat: BMC 2012-12-01
Col·lecció:Journal of Translational Medicine
Matèries:
Glioblastoma
Radiotherapy
Temozolomide
MGMT
Methylation
CD133
Accés en línia:http://www.translational-medicine.com/content/10/1/250
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars